OncoLens

We are excited to announce OncoLens' recognition by #INC5000 as one of the Fastest-Growing Private Companies in America, for the second year in a row! Congratulations Anju Mathew and the entire OncoLens Team! https://lnkd.in/gHpCYBru

Thank you BIP Ventures - we appreciate your support! And congratulations to all the other portfolio companies!

We're Hiring! Customer Success Manager Ideal role for those who excel in high-impact environments, can collaborate with various levels of healthcare providers, and serve as the primary contact for complex enterprise accounts. Key responsibilities include strategically expanding accounts and overseeing post-sale customer relationships from end to end. Reporting to the VP of Customer Success, this role offers direct access and empowerment to drive internal and customer impact. If this opportunity resonates with you, reach out to us today! https://lnkd.in/eNb9tPm2 #CustomerSuccess #Healthcare #software #startup

New Study on the Benefits of Cancer Survivorship Care Dr. Timothy Mullett, thoracic surgeon at University of Kentucky Markey Cancer Center and chair of the American College of Surgeons (#ACS) Commission on Cancer (#CoC), co-authored a groundbreaking study on the value of cancer survivorship care standards. This research underscores the importance of structured care programs for cancer survivors, aiming to enhance their quality of life and long-term health outcomes. The study highlights: - Improved patient outcomes with standardized care - The need for comprehensive follow-up plans - Strategies for integrating survivorship care into clinical practice and multidisciplinary collaboration Read more about this significant advancement in cancer care: Markey physician co-authors study on value of cancer survivorship care standards: https://lnkd.in/dcuTyf4d and the full study here - JAMA Network Open: https://lnkd.in/e7ZXKevr #SurvivorshipCare #MultidisciplinaryCancerCare #HealthcareInnovation #MedicalResearch

We're Hiring! Sr. Manager/Director of Sales, Provider Market. At OncoLens, we envision a world where every cancer patient has access to the best possible minds, therapies, and innovations in care – in time to make a difference. OncoLens is an AI-driven oncology care platform that delivers next-level multidisciplinary team collaboration, analytics, and clinical decision support tools. The OncoLens platform: - Integrates patient data across disparate data systems including EMRs, genomics, PACS, pathology, and more. - Extracts actionable informatics from structured and unstructured data to identify patients for clinical trials, biomarker testing, stem cell therapies, and more. - Enables multi-disciplinary care team collaboration within and across enterprises. Join us in revolutionizing cancer care. https://lnkd.in/e6dgyY5m #sales #healthcaresales #oncology #healthcare

Great to meet you too Wafik S. El-Deiry, MD, PhD, FACP #ASCO2024

Hope you had a great day at American Society of Clinical Oncology (ASCO) #ASCO24 . The OncoLens team is ready for day 3 to connect at booth 25149 and discuss Precision Patient ID for clinical trials and multidisciplinary care. Anju Mathew Chace Herndon James Noe OncoLens

Please stop by and see us at #ASCO24 Booth #25149 to learn more about our cancer-focused, multi-disciplinary treatment planning platform, why it’s used by more than 200 U.S. Cancer Centers and how it can benefit you. And say hi to Anju Mathew Lijo Simpson Chace Herndon and James Noe ! #MDT #clinicaltrials #AIAnalytics

Heading to #ASCO2024? Check out the American Society of Clinical Oncology (ASCO) Abstract on our advanced #NSCLC #QIP with Dwight H. Bon Secours Mercy Health, Youngstown, OH "Results of a quality improvement program to increase complete #lungcancer #biomarker testing rates by focusing on system, physician, and other factors associated with adverse health outcomes." The program achieved four improvements: 1) a 39.6% increase in Complete Biomarker Testing (CBT) in patients with advanced NSCLC (80.6% post-intervention) 2) a decrease of 15.7 days from diagnosis to complete liquid biopsy test results (27.2 days post-intervention) 3) increased CBT rates across all but one physician by an average of 55% (-5% to 220%) 4) increased CBT by 8% in females and patients with Medicare, Medicaid or other noncommercial/underinsured/uninsured payors. https://lnkd.in/eiTVTGmc And please stop by and see us at our Booth#: 25149!

We celebrate Clinical Trials Day on May 20, in recognition of what is often considered the start of the first randomized clinical trial. In 1747, James Lind began a clinical trial on this day to study the effects of different remedies for scurvy among sailors at sea. Times have changed and today the OncoLens team can take unstructured data from the EMR and conduct feasibility studies identify patterns and match patients to the right trials. !!! Now that is progress. #cancer #oncology #trials #EMR